Phase II Study to Evaluate Glivec (Imatinib Mesylate) to Induce Progression Arrest in Aggressive Fibromatosis / Desmoid Tumors Not Amenable to Surgical Resection With R0 Intent or Accompanied by Unacceptable Function Loss
Phase of Trial: Phase II
Latest Information Update: 05 May 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Fibroma
- Focus Therapeutic Use
- 07 Mar 2017 Results published in the European Journal of Cancer
- 10 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
- 10 May 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016.